CoChat
Sign Up
Cited by 134Radiomics and Machine Learning in Medical ImagingLung Cancer Diagnosis and TreatmentInflammatory Biomarkers in Disease Prognosis

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction

Open access
Vaidya, Pranjal, Bera, Kaustav, Gupta, Amit, Wang, Xiangxue, Corredor, Germán, Fu, Pingfu, Beig, Niha, Prasanna, Prateek, Patil, Pradnya D, Velu, Priya D, Rajiah, Prabhakar, Gilkeson, Robert, Feldman, Michael D, Choi, Humberto, Velcheti, Vamsidhar, Madabhushi, Anant·2020·The Lancet Digital Health
DOI 10.1016/s2589-7500(20)30002-9PMC PMC7051021
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Use of adjuvant chemotherapy in patients with early-stage lung cancer is controversial because no definite biomarker exists to identify patients who would receive added benefit from it. We aimed to develop and validate a quantitative radiomic risk score (QuRiS) and associated nomogram (QuRNom) for early-stage non-small cell lung cancer (NSCLC) that is prognostic of disease-free survival and predictive of the added benefit of adjuvant chemotherapy following surgery. Methods We did a retrospective multicohort study of individuals with early-stage NSCLC (stage I and II) who either received surgery alone or surgery plus adjuvant chemotherapy. We selected patients for whom we had available pre-treatment diagnostic CT scans and corresponding survival information. We used radiomic texture features derived from within and outside the primary lung nodule on chest CT scans of patients from the Cleveland Clinic Foundation (Cleveland, OH, USA; cohort D 1 ) to develop QuRiS. A least absolute shrinkage and selection operator-Cox regularisation model was used for data dimension reduction, feature selection, and QuRiS construction. QuRiS was independently validated on a cohort of patients from the University of Pennsylvania (Philadephia, PA, USA; cohort D 2 ) and a cohort of patients whose CT scans were derived from The Cancer Imaging Archive (cohort D 3 ). QuRNom was constructed by integrating QuRiS with tumour and node descriptors (according to the tumour, node, metastasis staging system) and lymphovascular invasion. The primary endpoint of the study was the assessment of the performance of QuRiS and QuRNom in predicting disease-free survival. The added benefit of adjuvant chemotherapy estimated using QuRiS and QuRNom was validated by comparing patients who received adjuvant chemotherapy versus patients who underwent surgery alone in cohorts D 1 –D 3 . Findings We included: 329 patients in cohort D 1 (73 [22%] had surgery plus adjuvant chemotherapy and 256 (78%) had surgery alone); 114 patients in cohort D 2 (33 [29%] had surgery plus adjuvant chemotherapy and 81 (71%) had surgery alone); and 82 patients in cohort D 3 (24 [29%] had surgery plus adjuvant chemotherapy and 58 (71%) had surgery alone). QuRiS comprised three intratumoral and 10 peritumoral CT-radiomic features and was found to be significantly associated with disease-free survival (ie, prognostic validation of QuRiS; hazard ratio for predicted high-risk vs predicted low-risk groups 1·56, 95% CI 1·08–2·23, p=0·016 for cohort D 1 ; 2·66, 1·24–5·68, p=0·011 for cohort D 2 ; and 2·67, 1·39–5·11, p=0·0029 for cohort D 3 ). To validate the predictive performance of QuRiS, patients were partitioned into three risk groups (high, intermediate, and low risk) on the basis of their corresponding QuRiS. Patients in the high-risk group were observed to have significantly longer survival with adjuvant chemotherapy than patients who underwent surgery alone (0·27, 0·08–0·95, p=0·042, for cohort D 1 ; 0·08, 0·01–0·42, p=0·0029, for cohorts D 2 and D 3 combined). As concerns QuRNom, the nomogram-estimated survival benefit was predictive of the actual efficacy of adjuvant chemotherapy (0·25, 0·12–0·55, p<0·0001, for cohort D 1 ; 0·13, <0·01–0·99, p=0·0019 for cohort D 3 ). Interpretation QuRiS and QuRNom were validated as being prognostic of disease-free survival and predictive of the added benefit of adjuvant chemotherapy, especially in clinically defined low-risk groups. Since QuRiS is based on routine chest CT imaging, with additional multisite independent validation it could potentially be employed for decision management in non-invasive treatment of resectable lung cancer. Funding National Cancer Institute of the US National Institutes of Health, National Center for Research Resources, US Department of Veterans Affairs Biomedical Laboratory Research and Development Service, Department of Defence, National Institute of Diabetes and Digestive and Kidney Diseases, Wallace H Coulter Foundation, Case Western Reserve University, and Dana Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2589-7500(20)30002-9

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 134

Related

See all

Metadata

Authors
Vaidya, P., Bera, K., Gupta, A., Wang, X., Corredor, G., Fu, P., Beig, N., Prasanna, P., Patil, P. D., Velu, P. D., Rajiah, P., Gilkeson, R., Feldman, M. D., Choi, H., Velcheti, V., & Madabhushi, A.
Affiliations
  • Case Western Reserve University (US)
  • University Hospitals of Cleveland (US)
  • Cleveland Clinic (US)
  • Weill Cornell Medicine (US)
  • Mayo Clinic (US)
  • University of Pennsylvania (US)
  • NYU Langone’s Laura and Isaac Perlmutter Cancer Center (US)
  • Louis Stokes Cleveland VA Medical Center (US)
Corresponding author
Madabhushi, Anant
ORCID
Venue
The Lancet Digital Health
Publisher
Elsevier BV
Published
2020-03
Volume
2
Issue
3
Pages
e116-e128
ISSN
2589-7500 (ISSN-L)
DOI
10.1016/s2589-7500(20)30002-9
PMC
PMC7051021
OpenAlex
W3006347021
Cited by
134
References
27
Citations by year
2026: 12 · 2025: 18 · 2024: 22 · 2023: 18 · 2022: 30 · 2021: 28 · 2020: 6
FWCI
9.98
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Digital Health (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Defense (W81XWH-18\u20131-0440, W81XWH-18, 1-0440)
  • National Institutes of Health (P50CA174523, 01A1, 1U24CA199374\u201301, 1P20 CA233216\u201301, R01 CA220581\u201301A1, 1U01 CA239055\u201301, R01CA202752\u201301A1, R01CA208236\u201301A1, R01 CA216579\u201301A1)
  • DOD Peer Reviewed Cancer Research Program (W81XWH-16\u20131-0329, 1-0329, W81XWH-16)
  • National Institute of Diabetes and Digestive and Kidney Diseases (1K25 DK115904\u201301A1)
  • National Cancer Institute
  • Wallace H. Coulter Foundation
  • Case Western Reserve University
  • Dana Foundation
  • National Center for Research Resources (IBX004121A, 1 C06 RR12463, 1 C06 RR12463\u201301)
  • Government of South Australia
  • U.S. Department of Veterans Affairs
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
radiomics, non-small cell lung cancer, adjuvant chemotherapy, early-stage lung cancer, disease-free survival, nomogram, texture features, computed tomography, prognostic score, lymphovascular invasion, TNM staging, surgical resection, treatment selection, LASSO Cox regression, model validation, The Cancer Imaging Archive, Cleveland Clinic Foundation, University of Pennsylvania
MeSH terms
Aged, Carcinoma, Non-Small-Cell Lung, Female, Forecasting, Humans, Male, Middle Aged, Neoplasm Staging, Retrospective Studies, Tomography, X-Ray Computed, Chemotherapy, Adjuvant, Outcome Assessment, Health Care, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review